The role of recombinant human erythropoietin (rHuEPO) in surgical oncology;Ruolo dell'eritropoietina umana ricombinante rHuEPO nella chirurgia oncologica

Tumori

Volumn 83, Issue 4 SUPPL. 2, 1997, Pages

  Mercuriali, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

autotransfusion; erythropoietin; surgical oncology

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER SURGERY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; HUMAN; ONCOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ANEMIA; BLOOD TRANSFUSION, AUTOLOGOUS; ERYTHROPOIETIN; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0030829944     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Asano Y., Okamura S., Shibuya T., Harada M., Niho Y.: Growth of clonogenic myeloblastic leukemia cells in the presence of human recombinant erythropoietin in addition to various human recombinant hemopoietic growth factors. Blood, 72: 1682-1386, 1988.
2. Berdel W.E., Oberberg D., Reufii B., Thiel E.: Studies on the role of recombinant human erythropoietin in growth regulation of human nonhematopoietic tumor cells in vitro. Ann. Hematol., 63: 5; 1991.
3. Blumberg N., Triulzi D.J., Heal J.M.: Transfusion-induced immunomodulation and its clinical consequences. Transf. Med. Revs., IV(4): 24-35; 1990.
4. Bursch O.R.C., Hop W.C.J., Hoynck van Papendrecht M.A.W., Marquet R.L., Jeekel J.: Blood transfusion and prognosis in colorectal cancer. N. Engl. J. Med., 1328: 1372-1376, 1993.
5. Bursch O.R.C., Hoynck van Papendrecht M.A.W., Marquet R.L., Jeekel J.: Experimental and clinical results of perioperative treatment with recombinant human erythropoietin. In: Pathophysiology and pharmacology of erythropoietin, Page H. et al., Eds., pp. 315-320, Springer Verlag, Berlin, 1992.
6. Cartwright G.E., Lee G.R.: The anemia of chronic disorders. Br. J. Haematol., 21: 147-152, 1971.
7. Case D.C., Jr., Sears D.A.: Anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am. J. Med., 87: 639-646, 1989.
8. DeGowin R.L., Gibson O.P.: Erythropoietin and the anemia of mice bearing extramedullary tumor. J. Lab. Clin. Med., 94: 303,1979.
9. Goodnough L.T., Rudnick S., Price T.H., Ballas S.K., Collins M.L., Crowley J.P., Kosmin M., Kruskall M.S., Lenes B.A., Menitove J.E., Silberstein L.E., Smith K.J., Wallas C.H., Abels R., Von Tress M.: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N. Engl. J. Med., 321: 1163-1168, 1989.
10. Heiss M.M., Mempel W., Jauch K.W., Delanoff C., Mayer G., Mempel M., Eissner H.J., Schildberg F.W.: Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet, 342: 1328-1333, 1993.
11. Lee G.: The anemia of chronic disease. Semin. Hematol., 20: 61-80: 1983.
12. Mercuriali F., Biffi E., Inghilleri G., Vinci A.: The role of preoperative autologous blood donation and intraoperative blood salvage. Erythropoiesis, 1: 47-55, 1990.
13. Mercuriali F., Biffi E., Inghilleri G., Vinci A.: Low hematocrit: limiting factor in autologous blood predonatio program. In: Transfusion in Europe, Castelli D., Genetet B., Habibi B., Nyddeger Y., Eds., pp. 291-298, Arnette S.A., Paris ISBT, 1989.
14. Mercuriali F., Gualtieri G., Sinigallia L., Inghilleri G., Biffi E., Vinci A., Colotti M.T., Barosi G., Lambertenghi Deliliers G.: Use of recombinant human erythropoietin to assist autologous blood donation by anemic reumathoid arthritis patients undergoing major orthopedic surgery. Transfusion, 34: 501-506, 1994.
15. Mercuriali F., Zanella A., Barosi G., Inghilleri G., Biffi E., Vinci A., Colotti M.T.: Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion, 33: 55-60, 1993.
16. Miller C.B., Platania L.C., Mills S.R., Zahurak M.L., Ratain M.J., Ettinger D.S., Jones R.J.: Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J. Natl. Cancer Inst., 84: 98-103, 1992.
17. Platanias L.C., Miller C.B., Mick R., Hart R.D., Ozer H., Mc-Evilly J.-M., Jones R.J., Ratain M.J.: Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J. Clin. Oncol., 9: 2021-2026, 1991.
18. Rothmann S.A., Paul P., Weick J.K.: Effect of cis-diaminedi-chloroplatinum on erythropoietin production and hematopoietic progenitor cells. International J. Cell Cloning, 3: 415-423, 1985.
19. Skillings J.R., Sridhar F.G., Wong C., Paddok L.: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am. J. Clin. Oncol., 16: 22-25, 1993.
20. Spivak J.L.: Recombinant human erythropoietin and anemia of cancer. Blood, 84: 997-1004, 1994.
21. Van Camp B.: Anemia in cancer. Erythropoiesis, 2: 39-40; 1991.
22. Walker R.H.: Transfusion risks. Am. J. Clin. Pathol., 88: 374-378, 1987.
23. Winearls C.G., Pippard M.J., Reid C., Downing M.R., Cotes P.M.: Effect of human erythropoietin from recombinant DNA on the anemia of patients maintained on chronic haemodialysis. Lancet, 2: 1175-1177, 1986.
24. Wu H.S., Little A.G.: Perioperative blood transfusions and cancer recurrence. J. Clin. Oncol., 6: 1348-1354, 1988.